Encorium Group, Inc. Announces $4.0 Million of Additional New Business Contracts

Encorium Group, Inc. (Nasdaq: ENCO), a leader in the design, development, and management of complex clinical trials and patient registries for many of the world's leading pharmaceutical and biotechnology companies, today announced that the Company signed multiple new contracts with an aggregate value of approximately $4.0 million during its second quarter ended June 30, 2007. These contracts, which are in addition to the $8.5 million of signed contracts announced over the past four weeks, are for developmental support of new clinical trials and various changes-of-scope for existing studies. The contracts are with multiple clients and are across numerous therapeutic areas including cardiovascular diseases, oncology, diabetes, infectious diseases, and immunology/vaccines. Encorium will provide a variety of services, including consulting and trial design, project management, field monitoring, data management, financial management, and quality assurance. Revenue recognition for these contracts principally began in the current third quarter and will occur on a proportional performance basis as services are performed on each project. Kenneth M. Borow, M.D., Chief Executive Officer for Encorium Group, commented, "I believe that Encorium is beginning to demonstrate a stronger competitive position as a consequence of our combination with Remedium last November. We are now seeing the benefits resulting from our increased geographic reach, our proficiencies and experience at the local country level, our expanded therapeutic area expertise, and having a more diverse client portfolio. In addition, the significant investments that we have made into new business development and marketing of the Encorium brand are showing very real results as reflected by the $12.5 million in contract signings in the second quarter of 2007.” Kai E. Lindevall, M.D., Ph.D., Encorium Group’s President, International Operations, Europe and Asia, stated, "We have developed strong momentum in our European and Asian operations with $13.3 million of new contracts signed in these geographic areas during the first six months of 2007. Many of these contracts represent repeat business with longstanding clients, a result that we believe reflects positively on the high quality of our operations. Our strategy of providing excellent consulting and operational services to emerging biotechnology companies is also generating new and exciting opportunities for Encorium. As a consequence, we have been able to form preferred provider partnerships with several of our clients. I am also quite proud of the recent successes that we have had within the Japanese biopharmaceutical market as reflected by last week’s new business announcement. We look forward to signing additional new business contracts with Japanese biopharmaceutical companies in the future.” About Encorium Group, Inc. Encorium Group, Inc. is a global clinical research organization that is a leader in the design and management of complex clinical trials and Patient Registries for the pharmaceutical, biotechnology and medical device industries. The Company’s mission is to provide its clients with high quality, full-service support for their biopharmaceutical and medical device development programs. Encorium offers therapeutic expertise, experienced team management and advanced technologies. The Company has drug and biologics development as well as clinical trial experience across a wide variety of therapeutic areas such as infectious diseases, cardiovascular, vaccines, oncology, endocrinology/metabolism, diabetes, gene therapy, immunology, neurology, gastroenterology, dermatology, hepatology, women’s health and respiratory medicine. Encorium believes that its leadership in the design of complex clinical trials, its therapeutic expertise and commitment to excellence, and its application of innovative technologies, offer its clients a means to more quickly and cost effectively move products through the clinical development process. Encorium is headquartered in Wayne, Pennsylvania with its European base of operations in Espoo, Finland. The Company has a geographic footprint that includes over one billion people in North America, Western/Central/Eastern Europe, Scandinavia, and the Baltics. This press release contains forward-looking statements identified by words such as "estimate,” "project,” "expect,” "intend,” "believe,” "anticipate” and similar expressions. Actual results might differ materially from those projected in, expressed in or implied by the forward-looking statements. Potential risks and uncertainties that could affect the Company's future operating results and financial condition include, without limitation: (i) our success in attracting new business and retaining existing clients and projects; (ii) the size, duration, and timing of clinical trials we are currently managing may change unexpectedly; (iii) the termination, delay or cancellation of clinical trials we are currently managing could cause revenues to decline unexpectedly; (iv) the timing difference between our receipt of contract milestone or scheduled payments and our incurring costs to manage these trials; (v) outsourcing trends in the pharmaceutical, biotechnology and medical device industries; (vi) the ability to maintain profit margins in a competitive marketplace; (vii) our ability to attract and retain qualified personnel; (viii) the sensitivity of our business to general economic conditions; (ix) other economic, competitive, governmental and technological factors affecting our operations, markets, products, services and prices; (x) announced awards received from existing and potential customers are not definitive until fully negotiated contracts are executed by the parties;(xi) our backlog may not be indicative of future revenues and may not generate the revenues expected;(xii) our ability to successfully integrate the businesses of Encorium and Remedium Oy which we acquired on November 1, 2006; and (xiii) ability of the combined businesses to operate successfully, generate revenue growth and operating profits. You should not place any undue reliance on these forward looking statements which speak only as of the date of this press release. Additional information concerning factors that might affect our business or stock price which could cause actual results to materially differ from those in forward-looking statements is contained in Encorium Group's SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2006 and other periodic reports under the Securities Exchange Act of 1934, as amended, copies of which are available upon request from Encorium Group's investor relations department or The Equity Group Inc.